Article:Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. (5380833)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q30234751. Its title is Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. and the publication date was 2017-03-22. The initial author is Yoshiko Iwasaki.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: BioMed Research International

Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease

  • Yoshiko Iwasaki
  • Junichiro James Kazama
  • Masafumi Fukagawa

1Department of Health Sciences, Oita University of Nursing and Health Sciences, Oita, Japan

2Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan

3Division of Nephrology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan

Publication date (ppub): /2017

Publication date (epub): 3/2017

Abstract

Prevention of bone fractures is one goal of therapy for patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), as indicated by the Kidney Disease: Improving Global Outcomes guidelines. CKD patients, including those on hemodialysis, are at higher risk for fractures and fracture-related death compared to people with normal kidney function. However, few clinicians focus on this issue as it is very difficult to estimate bone fragility. Additionally, uremia-related bone fragility has a more complicated pathological process compared to osteoporosis. There are many uremia-associated factors that contribute to bone fragility, including severe secondary hyperparathyroidism, skeletal resistance to parathyroid hormone, and bone mineralization disorders. Uremia also aggravates bone volume loss, disarranges microarchitecture, and increases the deterioration of material properties of bone through abnormal bone cells or excess oxidative stress. In this review, we outline the prevalence of fractures, the interaction of CKD-MBD with osteoporosis in CKD patients, and discuss possible factors that exacerbate the mechanical properties of bone.

Paper

1. Introduction

Elderly people are susceptible to diseases such as hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. Osteoporosis and chronic kidney disease (CKD) are also common, and the prevalence of these diseases is increasing globally, in part due to the increasing aging population. Osteoporosis under uremic conditions and management of the disease have not been widely studied. The prevalence and risk of fractures are higher in CKD patients compared to healthy people. Patients on dialysis, in particular, have an approximately fourfold greater risk for hip fractures than sex- and age-matched individuals in the general population [[1], [2]]. Their fracture risk correlates positively with age, duration of dialysis, high or low parathyroid hormone (PTH) level, female gender, low body mass index, and presence of peripheral vascular calcification. Several studies report that nondialysis patients aged over 50 with estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m2 also have a twofold greater risk for hip fractures than individuals without CKD [[3][7]]. A hip fracture critically limits activities of daily living and increases fracture-related mortality [[8][10]], and this trend is more evident in dialysis patients [[11], [12]]. Japanese dialysis patients, however, have relatively better prognosis with regard to survival after a hip fracture [[13]]. A tool called FRAX® that can predict fracture risk appears to be useful for predicting death among Japanese hemodialysis patients [[14]]. Even though it remains unclear why FRAX was useful to predict mortality in Japanese dialysis patients, elucidation of the pathogenesis of decreased bone strength and treatment of fractures in patients with CKD are important to improve survival and the quality of life in this patient population. In this review, we describe the current status of fragility fractures and their treatments in CKD patients.

2. Risk Factors of Fragility Fractures in CKD Patients

Clinicians and researchers agree that risk factors for fractures in CKD are complicated because patients have many abnormalities that may increase fracture incidence. Advanced muscle weakness [[15]], frailty [[16]], and deteriorated cognitive function [[17]] are potential contributors to increased risk for falling among CKD patients. Falls are especially common in older CKD patients [[18]]. Lack of exposure to sunlight, which contributes to muscle strength, may be a risk factor, because the risk for hip fractures tends to be higher in high-latitude regions of the United States [[19]]. Despite the high prevalence of hip fractures, clinical studies have failed to elucidate why falling affects the risk for hip fractures but not fractures of other parts of the body such as vertebrae and wrist. In addition, CKD patients also have deteriorated mineral metabolism.

3. Definitions of CKD-MBD, Renal Osteodystrophy, and Osteoporosis

The three key bone lesions accompanying CKD are CKD-mineral bone disorder (CKD-MBD), renal osteodystrophy, and osteoporosis, but their definitions are often ambiguous. CKD-MBD is a syndrome defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines as a systemic mineral metabolic disorder associated with CKD, which could result in disorders of bone metabolism and/or the cardiovascular system [[20]]. CKD-MBD consists of three components; abnormalities of calcium, phosphorus, PTH, and vitamin D metabolism; abnormalities in bone turnover, mineralization, volume, and strength; and soft tissue calcification including vascular calcification. This disease may manifest one component or any combination of the three. According to this definition, “renal osteodystrophy” indicates bone morphologic changes in patients with CKD and is one measure of the skeletal disorder component of CKD-MBD.

Bone lesions accompanying renal dysfunction are symptoms of CKD-MBD, but worsening of mechanical bone strength is not typically mentioned. Impairment of mechanical properties of bone comes under the term “osteoporosis,” as defined by the National Institute of Health. This pathophysiology is characterized by compromised bone strength predisposing a person to increased risk of fractures [[21]]. In this definition, bone strength is a composite of bone mass and bone quality. Bone mass is a strong determinant of bone strength and is useful as a diagnostic tool for osteoporosis in people with extremely low bone mass. As there are no other tools to predict and/or monitor bone strength in clinical practice, bone mass measurement is considered the most informative and useful tool available to diagnosis osteoporosis. Bone mass, however, is not the only determining factor. Other factors affecting bone mechanical strength include “bone quality.” Bone quality is used to describe the ability of bone to perform mechanical load-bearing functions. This definition includes all characteristics that influence the load-bearing capacity, including bone microarchitecture and material properties [[22], [23]], Table 1.

A question often arises as to which plays a more important role in bone mechanical strength, bone mass or bone quality. However, the contribution of each of the two parameters remains unclear, because several cohort studies suggest that one-half of all fragility fractures are observed in postmenopausal women with a T-score above −2.5 SD, the threshold for diagnosing osteoporosis defined by the World Health Organization [[24][26]]. Additionally, postmenopausal women with fragility fractures had poor bone microarchitecture and altered material properties, which influence bone mechanical properties [[27][29]]. Therefore, bone mass measurement is strictly not the standard method for diagnosing osteoporosis.

With the progression of renal function impairment, fracture risk is remarkably high in CKD. While we suspect that osteoporosis may underlie the increased risk of fracture in CKD, the mechanism may differ from that of primary osteoporosis characterized by marked reduction in bone mass. It is also unclear whether osteoporosis (bone fragility) associated with CKD is derived from CKD-MBD or factors other than CKD-MBD.

Both clinical and preclinical studies suggest that loss of bone strength in CKD patients has two possible components, loss of bone mass and deterioration of bone quality. The KDIGO guidelines published in 2009 do not recommend routine bone mineral density (BMD) testing because BMD does not predict fracture risk in patients with kidney disease as it does in the general population [[30]]. However, a recent meta-analysis reveals that BMD is significantly lower in predialysis patients with fracture compared to those without [[31]]. A prospective study has shown that BMD measured by dual X-ray absorptiometry (DXA) predicts incident fracture in stages 3–5 CKD patients, and the prediction ability is comparable to that using high-resolution peripheral quantitative computed tomography [[32]]. Furthermore, two studies have reported the assessment of BMD using DXA to predict fractures in CKD patients including those on hemodialysis [[33], [34]]. Therefore, BMD measured by DXA may be useful to assess loss of bone mass or fracture risk. On the other hand, cortical bone loss that increases in advanced stage of CKD is not well depicted by DXA. Therefore, DXA still has limited clinical utility in advanced stage of CKD. More attention should be paid to other factors affecting bone strength. Factors contributing to bone strength comprising bone loss and bone quality are discussed below and summarized in Table 2.

Progressive changes in serum biochemical parameters such as phosphorus, PTH, 1,25(OH)2 vitamin D3, and fibroblast growth factor 23 (FGF23) levels indicate CKD-related disturbances of mineral and endocrine factors [[35], [36]]. Increased PTH levels powerfully impact bone mechanical properties, because PTH modifies the activities of bone cells, which regulate bone turnover leading to altered bone mass. PTH stimulates the osteoclastic resorption and remodeling speed, thereby increasing bone turnover. Reduction in cortical BMD and thickness together with increase in cortical porosity assessed by DXA or high-resolution peripheral quantitated tomography (HR-pQCT) have been reported to result in increased bone fragility [[37][40]]. In stable dialysis patients, Kazama et al. [[41]] showed that circulating PTH level correlates inversely with cortical porosity but not with cancellous bone volume assessed by bone histomorphometry. Parathyroidectomy in patients on maintenance hemodialysis reduced fracture risk [[42]]. Additionally, elevated serum alkaline phosphatase due to excessive PTH secretion is associated with higher risk of hip fracture [[43]]. However, contradicting results on the relationship between PTH level and structure-related bone strength have also been reported [[44], [45]]. Moreover, medical and surgical treatments for severe hyperactive parathyroid function have progressed, and moderate hyperparathyroidism is unlikely to be a major risk factor for skeletal fragility.

Disturbed bone remodeling (marked decreases in both bone resorption and bone formation) caused by suppressed PTH secretion or skeletal resistance to the action of PTH under uremic condition exits in low-turnover bone lesions in CKD [[46][48]]. This condition is called “adynamic bone,” and is an increasingly common occurrence [[49], [50]]. Adynamic bone constitutes 50% of all CKD-MBD in patients on peritoneal dialysis and 19% in patients on hemodialysis [[30]]. Several clinical and animal studies have suggested an increased fracture risk in adynamic bone disease [[51][54]].

To summarize, the relationship between fracture risk and PTH level, which alters bone remodeling and bone microstructure, remains controversial. Regardless of high or low PTH level, it is currently difficult to predict fracture risk by PTH level.

FGF23 is derived from osteocytes and is an endocrine hormone that regulates phosphate metabolism. FGF23 stimulates urinary phosphate excretion, suppresses absorption in the gut, and accelerates degradation of 1,25(OH)2 vitamin D3 in response to a high phosphate diet or a state of impaired phosphate excretion as seen in CKD. FGF23 level is elevated prior to changes in phosphate, 1,25(OH)2 vitamin D3, and PTH levels accompanying decline in GFR [[55][57]]. While some studies reported an association between elevated FGF23 secondary to early CKD and risk of fracture in elderly men with decreased eGFR [[58][60]], other reports found no significant relationship [[61], [62]]. Isakova et al. [[63]] analyzed 2234 subjects and reported that FGF23 level was not associated with bone loss or fracture risk in a community-based population of well-functioning older adults. A recent report found that elevated FGF23 induced by high phosphorus diet increased the expression of secreted frizzled-related protein 4 and Diccopf-1, which are Wnt signal inhibitors, and inhibited the Wnt signal pathway [[64]]. Another report showed that FGF23 also had a physiological role in local bone mineralization, regulating osteopontin indirectly through transcriptional control of tissue nonspecific alkaline phosphatase in a vitamin D- and klotho-independent manner [[65]]. These reports suggest that high FGF23 level may affect bone fragility by decreasing mineralization through inhibition of the Wnt pathway.

Sclerostin is a Wnt pathway inhibitor secreted by osteocytes. The canonical Wnt/β-catenin signaling pathway directly affects osteoblast differentiation, proliferation, survival, and bone formation. Sclerostin antagonizes Wnt signaling and inactivates the pathway. The relationship between sclerostin and fracture risk is not consistent among studies [[66][69]]. Serum sclerostin is high in early CKD and is maintained at a high level in the advanced stages [[70][73]]. In an animal study, higher serum phosphate concentration derived from a high phosphorus diet was found to elevate sclerostin expression despite increased osteocyte apoptosis [[74]]. Combination therapy of anti-sclerostin antibody with PTH-suppressive agent was effective in improving bone mass and mechanical properties [[75]]. It is possible that a high sclerostin level is an aggravating factor of bone fragility.

Vitamin D [25(OH)D3 and 1,25(OH)2D3] deficiency and altered vitamin D metabolism occur in CKD patients. Because vitamin D is required for normal bone formation and mineralization, 25(OH)D3 deficiency (<15 nmoL) is associated with less bone formation and mineralization in trabecular bone [[76]]. A lower vitamin D status is associated with increased fracture incidence and risk [[77][80]]. Recently, Murali et al. [[65]] showed that 1,25(OH)2D3 inhibits local mineralization by augmenting the expression of the inhibitor osteopontin. To elucidate the involvement of 1,25(OH)2D3 in bone mineralization in CKD, further in vivo and in vitro experiments are required.

An increased incidence of bone fragility was observed in CKD irrespective of variations in PTH, 1,25(OH)2D3, FGF23, and sclerostin levels that reflect disturbances of mineral and endocrine metabolism. Factors other than CKD-MBD which may aggravate weakening of bone mechanical properties in CKD patients should be considered.

6. Uremic Conditions Deteriorate Bone Material Properties

Bone is composed of two organic materials, type I collagen and hydroxyapatite. The number of collagen crosslinks formed by both enzyme-induced and non-enzyme-induced processes as well as tissue mineral content (density) confer bone elasticity and strength. Various abnormalities in bone material properties are found in CKD patients.

The chemical composition of bone can be analyzed by vibrational spectroscopic methods such as Fourier transform infrared or Raman spectroscopy [[81], [82]]. These methods provide data on mineral parameters including the mineral-to-matrix ratio (indicating the degree of mineral apposition), the degree of carbonate substituting for phosphate in the apatite lattice, and crystallinity (representing the mineral crystal size and perfection). Additionally, collagen maturity can be obtained by calculating the ratio of mature crosslinks to immature crosslinks. Alterations of these parameters in the bones have been reported in animal models of CKD [[51], [83][85]] and bone biopsy samples from hemodialysis patients [[86], [87]].

Nonphysiological collagen crosslinks formed by the actions of advanced glycation end-products are modified crosslinks and are found in increased numbers in bone biopsy samples from dialysis patients [[88]] and animal models of CKD [[51], [83][85]]. Immunostaining analysis of bones in a rat model of CKD also demonstrated increase in crosslinks modified by advanced glycation end-products and reduced lysyl oxidase protein, an enzyme required for generating physiological collagen crosslinks [[89]]. The degree of biological bone apatite orientation, which is related to bone elasticity, was assessed by X-ray diffraction [[90]] and was found to be exacerbated in a rat model of early kidney injury [[84]]. Interestingly, in experimental uremic animals, these changes were complicated by the progression of renal dysfunction [[51]], and some changes were independent of bone turnover [[84]]. The changes were reduced by administration of AST-120, an oral charcoal adsorbent of uremic toxins [[83]]. AST-120 did not change mineral metabolism. Therefore, the uremic condition may modify the material properties directly.

Uremic conditions are known to create an excess oxidative stress environment [[91]]. Uremic condition or a specific uremic toxin inhibits osteoblasts [[92][96]] and osteoclasts [[97]]. Although whether the material properties are altered in CKD patients with fragile bone has not been confirmed, uremia-related osteoporosis causing bone fragility should exist in CKD.

7. Microcracks and Osteocyte Apoptosis

Because one of the purposes of bone remodeling is to repair microdamage that occurs in bone from daily mechanical stress, suppression or absence of remodeling will result in accumulation of microdamage. Excessive accumulation of microdamage can cause fragility fractures. Although there are no reports that indicate impaired microdamage repair in low-turnover bone associated with CKD, findings that suppressed bone turnover increases fragility and fracture risk suggest accumulation of microdamage [[98][100]].

The rates of osteocyte apoptosis and reduced density are higher in fractured bone than in normal bone [[101][103]]. Empty lacunae (absence of osteocytes in lacunae) are found in renal osteodystrophy. PTH fragment, especially the c-terminal PTH fragment, increases osteocyte apoptosis [[104]]. The c-terminal PTH fragment is accumulated in CKD, and the amount increases depending on renal insufficiency [[105]]. From these findings, increased osteocyte apoptosis appears to be associated with fragility fractures in CKD patients.

To summarize, bone fragility in CKD is probably caused by loss of bone mass and deterioration of bone quality through changes in blood levels of humoral factors and the presence of uremic toxins (Figure 1).

8. Pharmacological Therapeutics for Bone Fractures in CKD Patients

In the general population, pharmacotherapy is the mainstay of management for osteoporosis. Patients with primary osteoporosis are treated with different types of drugs. Guidelines for primary osteoporosis recommend antiresorptive drugs (bisphosphonates, antagonists of osteoclasts, and selective estrogen receptor modulators) and stimulators of bone formation (teriparatide) as well as active vitamin D and calcium supplementation. However, these drugs present problems for CKD patients, because some are excreted via the kidneys. The KDIGO guidelines [[30]] indicate that extrapolating results from studies of osteoporosis in general population to patients with CKD stages 3–5D may not be valid, with concerns over long-term safety because the pathogenesis differs between primary osteoporosis and CKD-MBD-related osteoporosis. On the other hand, due to the increases in osteoporosis and CKD with advancing age and the proven safety profile of osteoporotic agents, the KDIGO guidelines approve the use of these agents in early CKD patients with high risk of fracture, including patients with osteoporosis and CKD stages 1-2. Potential treatments with antiosteoporotic agents in different CKD stages are summarized in Table 3. Additional information for some agents will be discussed in detail below.

Although bisphosphonates have become a standard treatment for osteoporosis, bisphosphonates should not be used in patients with stages 4-5 CKD because these drugs are excreted by the kidney. The accumulation of bisphosphonates in bone also needs to be considered. Ott [[106]] reported the accumulation of bisphosphonate in the bone of dialysis patients treated with these agents. The use of bisphosphonate in dialysis is a growing concern, as there is the possibility of causing “frozen bone” with extremely low bone turnover. Bisphosphonate exposure over a 5.5-year period was reported to aggravate bone viscoelasticity and provoke atypical femoral fractures [[107]]. This phenomenon may be a consequence of reduced heterogeneity of material properties through suppressed bone turnover [[108]]. Use of bisphosphonates may increase the fracture risk through exacerbation of bone mechanical properties and increase atypical fractures [[109][111]]. Since the degree of bisphosphonate accumulation and the efficacy of bisphosphonates both depend on their affinity to hydroxyapatite, existing data suggest treatment durations of up to 5 years with alendronate, 3 years with zoledronate, and 1 year with risedronate, although the optimal length of a “drug holiday” has not been established [[112]]. If it is necessary to use bisphosphonates for the management of severe osteoporosis in patients with CKD, bisphosphonates that have low affinity to hydroxyapatite crystals, such as risedronate and ibandronate, should be chosen.

Denosumab, a human monoclonal antibody for the receptor activator of nuclear factor-kappa B, does not accumulate in the body because its point of action is limited. Its efficacy in CKD is expected to be the same as that in primary osteoporosis. A previous study reported that the efficacy of denosumab, which increases BMD and suppresses fractures, did not differ depending on kidney function [[113]]. Another study reported that denosumab significantly increased BMD of the lumber spine and femoral neck in hemodialysis patients, although the sample size was small [[114]]. Denosumab may induce hypocalcemia through strong suppression of bone resorption, which tends to be amplified in CKD patients [[115]]. Denosumab should be prescribed with active vitamin D to regulate the calcium balance.

Raloxifene, a selective estrogen receptor modulator improved BMD in postmenopausal women with CKD, and greater increases in BMD were associated with lower creatinine clearance [[116]]. In another study, patients on raloxifene showed slower progression of kidney disorders and significantly fewer kidney-related adverse events compared to the placebo group [[117]]. However, reduced serum calcium concentration and increased PTH secretion were reported.

Teriparatide is a recombinant protein of PTH (1–34) and an anabolic agent for the treatment of postmenopausal osteoporosis. Although teriparatide should be used with caution in osteoporotic patients with CKD due to higher blood PTH level in secondary hyperparathyroidism associated with CKD, intermittent PTH administration can be used to induce an anabolic effect on bone in CKD. Some studies have reported that teriparatide treatment increases BMD [[118][120]] and ameliorates bone turnover [[120]]. Subjects of these studies showed decreased endogenous PTH concentration compared to appropriate controls. The effect of teriparatide treatment on CKD patients with normal or slightly higher PTH remains unknown.

Anti-sclerostin monoclonal humanized antibodies such as romosozumab and blosozumab, a new class of drugs with novel mechanisms of action, are being developed for osteoporosis treatment. In clinical trials, romosozumab and blosozumab have been shown to increase bone mass concomitant with increase in bone formation marker and decreases in bone resorption markers [[121], [122]]. Increases not only in trabecular BMD but also in cortical thickness and stiffness assessed by HR-pQCT were observed in subjects taking romosozumab compared to placebo controls [[123]]. Although elevated levels of sclerostin have been reported in CKD stages 3 to 5D patients [[73], [124], [125]], there are no clinical data on anti-sclerostin antibody treatment in CKD patients. In phase 2 in clinical trial of romosozumab, subjects who had estimated creatinine clearance as low as 30 mL/min were included [[121]]. Since romosozumab was associated with favorable effects on bone turnover in that study population, its efficacy in improving bone fragility in CKD patients may be anticipated.

In addition to the apparent relationship between sclerostin and bone strength, blood level of sclerostin has been shown to be associated with aorta valve calcification [[126]] and cardiovascular mortality in CKD patients [[127], [128]]. Further studies are needed to investigate the efficacy of sclerostin antibody treatment not only for fracture prevention but also for reducing cardiovascular mortality in CKD patients.

Control of hyperphosphatemia is important for CKD patients to prevent cardiovascular events and reduce the risk of death. From a secondary analysis of the EVOLVE trial, cinacalcet reduced the rate of clinical fractures by 16–29% [[129]]. The BONAFIDE trial demonstrated that long-term treatment with cinacalcet substantially reduced PTH and diminished elevated bone turnover as well as several biomarkers [[130]]. Yamamoto et al. [[131]] reported that dialysis patients who received angiotensin-converting enzyme inhibitors or angiotensin II type I receptor blockers had an approximately 30% lower risk of hospitalization for any fracture. It is possible that, in addition to traditional antiosteoporotic drugs, the use of inhibitors of specific pathophysiological conditions associated with renal failure is an appropriate strategy for the treatment of osteoporosis in CKD.

9. Conclusion

Determining the pathogenesis of osteoporosis and treatment efficacy is difficult in CKD patients because of the complicated mineral and bone abnormalities in these patients. As described above, many factors such as BMD, humoral factors, and alterations of material properties potentially affect bone strength. However, the factors that contribute to bone strength in the setting of CKD and their mechanisms of action remain unknown. For example, no changes in structural parameters and bone mechanical parameters were observed 6 months after kidney transplantation, even though BMD was ameliorated [[132]]. Other report revealed that cortical porosity is not superior to BMD determined by DXA hofr identification of HD patients with fragility fracture [[133]]. Moreover, clinical assessment of human femoral mechanical properties by reference point indentation (RPI), which is a novel technique that allows direct measurement of bone material or biomechanical properties, indicated that BMD did not discriminate fracture cases form controls [[134]]. These recent studies suggest that bone strength in CKD patients may be affected by many factors in a complicated manner, and the major factor and its degree of contribution remain unidentified. Therefore, more studies are required to assess bone mechanical properties using a multitude of factors including BMD and humoral factors. If PRI can be used easily in clinical studies, we may be able to discuss the diagnosis or grading of bone fragility in CKD patients. CKD patients are at increased risk for fractures regardless of whether they are on dialysis. The KDIGO working group is scheduling a selective revision of the guidelines [[135]]. However, until then, patients at risk of fragility fractures still need to be managed. Researchers, clinicians, pharmacologists, nurses, drug companies, and other authorities should pay particular attention to osteoporosis in CKD patients to determine suitable management.

References

  1. A. M. AlemD. J. SherrardD. L. GillenIncreased risk of hip fracture among patients with end-stage renal diseaseKidney International200058139639910.1046/j.1523-1755.2000.00178.x2-s2.0-003392072810886587
  2. M. CocoH. RushIncreased incidence of hip fractures in dialysis patients with low serum parathyroid hormoneAmerican Journal of Kidney Diseases20003661115112110.1053/ajkd.2000.198122-s2.0-003365956311096034
  3. T. L. NickolasD. J. McMahonE. ShaneRelationship between moderate to severe kidney disease and hip fracture in the United StatesJournal of the American Society of Nephrology200617113223323210.1681/ASN.20051111942-s2.0-3375070113517005938
  4. K. E. EnsrudL.-Y. LuiB. C. TaylorRenal function and risk of hip and vertebral fractures in older womenArchives of Internal Medicine2007167213313910.1001/archinte.167.2.1332-s2.0-3384641142417242313
  5. S. A. JamalD. C. BauerK. E. EnsrudAlendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trialJournal of Bone and Mineral Research200722450350810.1359/jbmr.0701122-s2.0-3424965366317243862
  6. L. F. FriedM. L. BiggsM. G. ShlipakAssociation of kidney function with incident hip fracture in older adultsJournal of the American Society of Nephrology200718128228610.1681/asn.20060505462-s2.0-3384599186417167115
  7. A. C. DooleyN. S. WeissB. KestenbaumIncreased risk of hip fracture among men with CKDAmerican Journal of Kidney Diseases2008511384410.1053/j.ajkd.2007.08.0192-s2.0-3734904575618155531
  8. A. TrombettiF. HerrmannP. HoffmeyerM. A. SchurchJ. P. BonjourR. RizzoliSurvival and potential years of life lost after hip fracture in men and age-matched womenOsteoporosis International200213973173710.1007/s0019802001002-s2.0-003671295912195537
  9. P. HaentjensJ. MagazinerC. S. Colón-EmericMeta-analysis: excess mortality after hip fracture among older women and menAnnals of Internal Medicine2010152638039010.7326/0003-4819-152-6-201003160-000082-s2.0-7795090333320231569
  10. A. MittalhenkleD. L. GillenC. O. Stehman-BreenIncreased risk of mortality associated with hip fracture in the dialysis populationAmerican Journal of Kidney Diseases200444467267910.1053/j.ajkd.2004.07.0012-s2.0-454422921215384018
  11. J. C.-F. LinW.-M. LiangMortality and complications after hip fracture among elderly patients undergoing hemodialysisBMC Nephrology2015161, article 10010.1186/s12882-015-0099-02-s2.0-84936851706
  12. C.-H. KuoT.-C. HsiehC.-H. WangIncreased risks of mortality and atherosclerotic complications in incident hemodialysis patients subsequently with bone fractures: a nationwide case-matched cohort studyPLoS ONE2015104e012170510.1371/journal.pone.01217052-s2.0-84929462581
  13. F. TentoriK. McCulloughR. D. KilpatrickHigh rates of death and hospitalization follow bone fracture among hemodialysis patientsKidney International201485116617310.1038/ki.2013.2792-s2.0-8489156073723903367
  14. T. HayashiN. JokiY. TanakaThe FRAX® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up studyJournal of Bone and Mineral Metabolism201533667468310.1007/s00774-014-0631-52-s2.0-8494544079425691284
  15. P. StenvinkelJ. J. CarreroF. von WaldenT. A. IkizlerG. A. NaderMuscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategiesNephrology Dialysis Transplantation20163171070107710.1093/ndt/gfv122
  16. C. DelgadoS. ShiehB. GrimesAssociation of self-reported frailty with falls and fractures among patients new to dialysisAmerican Journal of Nephrology201542213414010.1159/0004390002-s2.0-8494225046426381744
  17. M. MaravicA. OstertagP. UrenaM. Cohen-SolalDementia is a major risk factor for hip fractures in patients with chronic kidney diseaseOsteoporosis International20162741665166910.1007/s00198-015-3429-y2-s2.0-8494777183526588907
  18. C. DesmetC. BeguinC. SwineM. JadoulFalls in hemodialysis patients: prospective study of incidence, risk factors, and complicationsAmerican Journal of Kidney Diseases200545114815315696454
  19. J. B. WetmoreJ. LiuH. S. WirtzGeovariation in fracture risk among patients receiving hemodialysisClinical Journal of the American Society of Nephrology20161181413142110.2215/cjn.1165111527269611
  20. S. MoeT. DrüekeJ. CunninghamDefinition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International200669111945195310.1038/sj.ki.50004142-s2.0-3364575792016641930
  21. NIH Consensus Development Panel on Osteoporosis PreventionOsteoporosis prevention, diagnosis, and therapyThe Journal of the American Medical Association2001285678579510.1001/jama.285.6.78511176917
  22. M. L. BouxseinBone quality: where do we go from here?Osteoporosis International200314supplement 5S118S12714504716
  23. D. FelsenbergS. BoonenThe bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis managementClinical Therapeutics200527111110.1016/j.clinthera.2004.12.0202-s2.0-1484432300015763602
  24. E. S. SirisP. D. MillerE. Barrett-ConnorIdentification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentJournal of the American Medical Association2001286222815282210.1001/jama.286.22.28152-s2.0-003585203411735756
  25. E. Sornay-RenduF. MunozP. GarneroF. DuboeufP. D. DelmasIdentification of osteopenic women at high risk of fracture: the OFELY studyJournal of Bone and Mineral Research200520101813181910.1359/jbmr.0506092-s2.0-2544443820816160738
  26. S. C. E. SchuitM. Van Der KliftA. E. A. M. WeelFracture incidence and association with bone mineral density in elderly men and women: The Rotterdam StudyBone200434119520210.1016/j.bone.2003.10.0012-s2.0-094226814414751578
  27. E. M. SteinA. KepleyM. WalkerSkeletal structure in postmenopausal women with osteopenia and fractures is characterized by abnormal trabecular plates and cortical thinningJournal of Bone and Mineral Research20142951101110910.1002/jbmr.21442-s2.0-8489908227624877245
  28. Y. BalaR. ZebazeA. Ghasem-ZadehCortical porosity identifies women with osteopenia at increased risk for forearm fracturesJournal of Bone and Mineral Research20142961356136210.1002/jbmr.21672-s2.0-8490127182724519558
  29. F. MalgoN. A. T. HamdyS. E. PapapoulosN. M. Appelman-DijkstraBone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral densityJournal of Clinical Endocrinology and Metabolism201510052039204510.1210/jc.2014-43462-s2.0-8492933665425768670
  30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work GroupKIDGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral bone disorder (CKD-MBD)Kidney International2009113S1S130
  31. R. C. BucurD. D. PanjwaniL. TurnerT. RaderS. L. WestS. A. JamalLow bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-analysisOsteoporosis International201526244945810.1007/s00198-014-2813-32-s2.0-8492549398525477230
  32. S. L. WestC. E. LokL. LangsetmoBone mineral density predicts fractures in chronic kidney diseaseJournal of Bone and Mineral Research201530591391910.1002/jbmr.24062-s2.0-8492773177625400209
  33. S. IimoriY. MoriW. AkitaDiagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort studyNephrology Dialysis Transplantation201227134535110.1093/ndt/gfr3172-s2.0-84855972334
  34. R. H. YenchekJ. H. IxM. G. ShlipakBone mineral density and fracture risk in older individuals with CKDClinical Journal of the American Society of Nephrology2012771130113610.2215/CJN.1287121122516286
  35. S. M. MoeT. DrüekeN. LameireG. EknoyanChronic kidney disease–mineral-bone disorder: a new paradigmAdvances in Chronic Kidney Disease200714131210.1053/j.ackd.2006.10.0052-s2.0-3384574546217200038
  36. M. G. VervloetZ. A. MassyV. M. BrandenburgBone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disordersThe Lancet Diabetes and Endocrinology20142542743610.1016/s2213-8587(14)70059-22-s2.0-8489966920724795256
  37. A. M. ParfittA structural approach to renal bone diseaseJournal of Bone and Mineral Research19981381213122010.1359/jbmr.1998.13.8.12132-s2.0-00318574899718188
  38. S. M. OttReview article: bone density in patients with chronic kidney disease stages 4-5Nephrology200914439540310.1111/j.1440-1797.2009.01159.x2-s2.0-6765073948119563381
  39. T. L. NickolasM. B. LeonardE. ShaneChronic kidney disease and bone fracture: a growing concernKidney International200874672173110.1038/ki.2008.2642-s2.0-5084913253718563052
  40. T. L. NickolasE. M. SteinE. DworakowskiRapid cortical bone loss in patients with chronic kidney diseaseJournal of Bone and Mineral Research20132881811182010.1002/jbmr.19162-s2.0-8488121968823456850
  41. J. J. KazamaR. KodaS. YamamotoI. NaritaF. GejyoA. TokumotoCancellous bone volume is an indicator for trabecular bone connectivity in dialysis patientsClinical Journal of the American Society of Nephrology20105229229810.2215/CJN.041506092-s2.0-7774933465620093344
  42. K. D. RudserI. H. de BoerA. DooleyB. YoungB. KestenbaumFracture risk after parathyroidectomy among chronic hemodialysis patientsJournal of the American Society of Nephrology20071882401240710.1681/asn.200701002217634437
  43. Y. MaruyamaM. TaniguchiJ. J. KazamaA higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in JapanNephrology Dialysis Transplantation20142981532153810.1093/ndt/gfu0552-s2.0-84904972712
  44. A. TrombettiC. StoermannT. ChevalleyAlterations of bone microstructure and strength in end-stage renal failureOsteoporosis International20132451721173210.1007/s00198-012-2133-42-s2.0-8488501981923100118
  45. A. L. NegriE. E. Del ValleM. B. ZanchettaEvaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patientsOsteoporosis International201223102543255010.1007/s00198-011-1890-92-s2.0-8486733539422234812
  46. M. FukagawaJ. J. KazamaT. ShigematsuSkeletal resistance to PTH as a basic abnormality underlying uremic bone diseasesAmerican Journal of Kidney Diseases2001384, supplement 1S152S15510.1053/ajkd.2001.274262-s2.0-003481622411576943
  47. Y. IwasakiH. YamatoT. Nii-KonoInsufficiency of PTH action on bone in uremiaKidney International Supplements2006102S34S3610.1038/sj.ki.50016002-s2.0-33745633043
  48. J. BoverP. UreñaV. BrandenburgAdynamic bone disease: from bone to vessels in chronic kidney diseaseSeminars in Nephrology201434662664010.1016/j.semnephrol.2014.09.0082-s2.0-8491576778425498381
  49. H. H. MallucheH. MawadM.-C. Monier-FaugereThe importance of bone health in end-stage renal disease: out of the frying pan, into the fire?Nephrology Dialysis Transplantation200419, supplement 1i9i1310.1093/ndt/gfh10022-s2.0-1842575839
  50. D. J. SherrardG. HerczY. PeiThe spectrum of bone disease in end-stage renal failure—an evolving disorderKidney International199343243644210.1038/ki.1993.642-s2.0-00271784398441240
  51. Y. IwasakiJ. J. KazamaH. YamatoM. FukagawaChanges in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney diseaseBone20114861260126710.1016/j.bone.2011.03.6722-s2.0-7995590360621397740
  52. K. AtsumiK. KushidaK. YamazakiS. ShimizuA. OhmuraT. InoueRisk factors for vertebral fractures in renal osteodystrophyAmerican Journal of Kidney Diseases199933228729310.1016/S0272-6386(99)70302-12-s2.0-003296612610023640
  53. B. PirainoT. ChenL. CoopersteinG. SegreJ. PuschettFractures and vertebral bone mineral density in patients with renal osteodystrophyClinical Nephrology198830257622-s2.0-00237626603180516
  54. A. H. NgS. OmelonF. VariolaAdynamic bone decreases bone toughness during aging by affecting mineral and matrixJournal of Bone and Mineral Research201631236937910.1002/jbmr.27022-s2.0-8495931583826332924
  55. P. EvenepoelB. MeijersL. ViaeneFibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidismClinical Journal of the American Society of Nephrology2010571268127610.2215/cjn.082411092-s2.0-7795478338020448073
  56. T. IsakovaP. WahlG. S. VargasFibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International201179121370137810.1038/ki.2011.472-s2.0-7995787013521389978
  57. C. NakanoT. HamanoN. FujiiCombined use of vitamin D status and FGF23 for risk stratification of renal outcomeClinical Journal of the American Society of Nephrology20127581081910.2215/CJN.086808112-s2.0-8486038737222362065
  58. M. A. I. MirzaM. K. KarlssonD. MellströmSerum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly menJournal of Bone and Mineral Research201126485786410.1002/jbmr.2632-s2.0-7995304673620928885
  59. N. E. LaneN. ParimiM. CorrAssociation of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) studyJournal of Bone and Mineral Research201328112325233210.1002/jbmr.19852-s2.0-8488683472723677793
  60. E. KandaM. YoshidaS. SasakiApplicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patientsBMC Nephrology2012131, article 12210.1186/1471-2369-13-1222-s2.0-84866551561
  61. A. JovanovichP. BùžkováM. ChoncholFibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health studyJournal of Clinical Endocrinology and Metabolism20139883323333110.1210/jc.2013-11522-s2.0-8488150388123771921
  62. L. DesjardinsS. LiabeufC. RenardFGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stagesOsteoporosis International20122372017202510.1007/s00198-011-1838-02-s2.0-8486358329222109743
  63. T. IsakovaX. CaiJ. LeeAssociations of FGF23 with change in bone mineral density and fracture risk in older individualsJournal of Bone and Mineral Research201631474274810.1002/jbmr.27502-s2.0-8495268396726590361
  64. N. Carrillo-LópezS. PanizoC. Alonso-MontesDirect inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney diseaseKidney International2016901778910.1016/j.kint.2016.01.02427165819
  65. S. K. MuraliP. RoschgerU. ZeitzK. KlaushoferO. AndrukhovaR. G. ErbenFGF23 regulates bone mineralization in a 1,25(OH)2D3 and Klotho-independent mannerJournal of Bone and Mineral Research201631112914210.1002/jbmr.26062-s2.0-8495743731626235988
  66. A. ArasuP. M. CawthonL.-Y. LuiSerum sclerostin and risk of hip fracture in older caucasian womenJournal of Clinical Endocrinology and Metabolism20129762027203210.1210/jc.2011-34192-s2.0-8486198532622466341
  67. M.-S. M. ArdawiA. A. RouziS. A. Al-SibianiN. S. Al-SenaniM. H. QariS. A. MousaHigh serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research studyJournal of Bone and Mineral Research201227122592260210.1002/jbmr.17182-s2.0-8486939006022836717
  68. P. GarneroE. Sornay-RenduF. MunozO. BorelR. D. ChapurlatAssociation of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY studyOsteoporosis International201324248949410.1007/s00198-012-1978-x2-s2.0-8487372606222525978
  69. P. SzulcC. BertholonO. BorelF. MarchandR. ChapurlatLower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS studyJournal of Bone and Mineral Research201328485586410.1002/jbmr.18232-s2.0-8487518661623165952
  70. Y. SabbaghF. G. GraciolliS. O'BrienRepression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophyJournal of Bone and Mineral Research20122781757177210.1002/jbmr.16302-s2.0-8486415275122492547
  71. D. CejkaJ. HerberthA. J. BranscumSclerostin and dickkopf-1 in renal osteodystrophyClinical Journal of the American Society of Nephrology20116487788210.2215/CJN.065508102-s2.0-7995555211021164019
  72. S. ThambiahR. RoplekarP. ManghatCirculating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffnessCalcified Tissue International201290647348010.1007/s00223-012-9595-42-s2.0-8486428071922527202
  73. S. PelletierL. DubourgM.-C. CarlierA. Hadj-AissaD. FouqueThe relation between renal function and serum sclerostin in adult patients with CKDClinical Journal of the American Society of Nephrology20138581982310.2215/CJN.076707122-s2.0-8487764181923430206
  74. J. C. FerreiraG. O. FerrariK. R. NevesEffects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin?PLoS ONE2013811e7972110.1371/journal.pone.00797212-s2.0-84893365468
  75. C. L. NewmanN. X. ChenE. SmithCompromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventionsBone201577505610.1016/j.bone.2015.04.0212-s2.0-8492834469325892482
  76. G. CoenD. MantellaM. Manni25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophyKidney International20056841840184810.1111/j.1523-1755.2005.00603.x2-s2.0-3164443954216164662
  77. C. AmbrusC. AlmasiK. BertaVitamin D insufficiency and bone fractures in patients on maintenance hemodialysisInternational Urology and Nephrology201143247548210.1007/s11255-010-9723-x2-s2.0-7995976045020237846
  78. H. A. Bischoff-FerrariW. C. WillettJ. B. WongPrevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trialsArchives of Internal Medicine2009169655156110.1001/archinternmed.2008.6002-s2.0-6384928268419307517
  79. R. ScraggVitamin D and public health: an overview of recent research on common diseases and mortality in adulthoodPublic Health Nutrition20111491515153210.1017/s13689800110014552-s2.0-8005351251321729467
  80. H. A. Bischoff-FerrariW. C. WillettE. J. OravA pooled analysis of vitamin D dose requirements for fracture preventionThe New England Journal of Medicine20123671404910.1056/nejmoa11096172-s2.0-8486352651822762317
  81. E. P. PaschalisR. MendelsohnA. L. BoskeyInfrared assessment of bone quality: a reviewClinical Orthopaedics and Related Research201146982170217810.1007/s11999-010-1751-42-s2.0-7996096601621210314
  82. M. D. MorrisG. S. MandairRaman assessment of bone qualityClinical Orthopaedics and Related Research201146982160216910.1007/s11999-010-1692-y2-s2.0-7996095253521116756
  83. Y. IwasakiJ. J. KazamaH. YamatoH. ShimodaM. FukagawaAccumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney diseaseBone201357247748310.1016/j.bone.2013.07.0372-s2.0-8488672136123920356
  84. Y. IwasakiJ. J. KazamaH. YamatoA. MatsugakiT. NakanoM. FukagawaAltered material properties are responsible for bone fragility in rats with chronic kidney injuryBone20158124725410.1016/j.bone.2015.07.0152-s2.0-8493822041226187196
  85. C. L. NewmanS. M. MoeN. X. ChenCortical bone mechanical properties are altered in an animal model of progressive chronic kidney diseasePLoS ONE201496e9926210.1371/journal.pone.00992622-s2.0-84902577352
  86. H. H. MallucheD. S. PorterM.-C. Monier-FaugereH. MawadD. PienkowskiDifferences in bone quality in low- and high-turnover renal osteodystrophyJournal of the American Society of Nephrology201223352553210.1681/ASN.20101212532-s2.0-8485793591822193385
  87. H. IsakssonM. J. TurunenL. RieppoInfrared spectroscopy indicates altered bone turnover and remodeling activity in renal osteodystrophyJournal of Bone and Mineral Research20102561360136610.1002/jbmr.102-s2.0-7795348666020200925
  88. J. MitomeH. YamamotoM. SaitoK. YokoyamaK. MarumoT. HosoyaNonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patientsCalcified Tissue International201188652152910.1007/s00223-011-9488-y2-s2.0-7995975724821499867
  89. C. AokiK. UtoK. HondaY. KatoH. OdaAdvanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophyLaboratory Investigation201393111170118310.1038/labinvest.2013.1052-s2.0-8488679437723979426
  90. T. NakanoK. KaibaraY. TabataUnique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer systemBone200231447948710.1016/s8756-3282(02)00850-52-s2.0-003679494112398943
  91. J. HimmelfarbUremic toxicity, oxidative stress, and hemodialysis as renal replacement therapySeminars in Dialysis200922663664310.1111/j.1525-139X.2009.00659.x2-s2.0-7154912044020017834
  92. Y. Iwasaki-IshizukaH. YamatoT. Nii-KonoK. KurokawaM. FukagawaDownregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover boneNephrology Dialysis Transplantation20052091904191110.1093/ndt/gfh8762-s2.0-24044508606
  93. J. J. KazamaS. YamamotoI. NaritaS. KuriharaNuclear chromatin-concentrated osteoblasts in renal bone diseasesTherapeutic Apheresis and Dialysis201115191310.1111/j.1744-9987.2011.00919.x2-s2.0-7995619043321595845
  94. T. Nii-KonoY. IwasakiM. UchidaIndoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cellsKidney International200771873874310.1038/sj.ki.50020972-s2.0-3424721926517264878
  95. H. TanakaY. IwasakiH. Yamatop-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathwaysBone201356234735410.1016/j.bone.2013.07.0022-s2.0-8488096167823851293
  96. S. YanoT. YamaguchiI. KanazawaThe uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failureNephrology Dialysis Transplantation200722113160316510.1093/ndt/gfm4552-s2.0-36749037260
  97. A. MozarL. LouvetC. GodinIndoxyl sulphate inhibits osteoclast differentiation and functionNephrology Dialysis Transplantation20122762176218110.1093/ndt/gfr6472-s2.0-84861884567
  98. J. BacchettaS. BoutroyL. JuillardBone imaging and chronic kidney disease: will high-resolution peripheral tomography improve bone evaluation and therapeutic management?Journal of Renal Nutrition2009191444910.1053/j.jrn.2008.10.0232-s2.0-5804915459219121770
  99. Z. Seref-FerlengezO. D. KennedyM. B. SchafflerBone microdamage, remodeling and bone fragility: how much damage is too much damage?BoneKEy Reports20154, article 64410.1038/bonekey.2015.11
  100. H. H. MallucheD. S. PorterD. PienkowskiEvaluating bone quality in patients with chronic kidney diseaseNature Reviews Nephrology201391167168010.1038/nrneph.2013.1982-s2.0-8489078891824100399
  101. C. R. DunstanN. M. SomersR. A. EvansOsteocyte death and hip fractureCalcified Tissue International199353supplement 1S113S11710.1007/bf016734172-s2.0-00272100688275364
  102. J. PowerB. S. NobleN. LoveridgeK. L. BellN. RushtonJ. ReeveOsteocyte lacunar occupancy in the femoral neck cortex: an association with cortical remodeling in hip fracture cases and controlsCalcified Tissue International2001691131910.1007/s00223-001-0013-62-s2.0-003492309211685428
  103. J. Delgado-CalleJ. ArozamenaR. García-RenedoOsteocyte deficiency in hip fracturesCalcified Tissue International201189432733410.1007/s00223-011-9522-02-s2.0-8275516085421874545
  104. F. R. BringhurstPTH receptors and apoptosis in osteocytesJournal of Musculoskeletal Neuronal Interactions2002232452512-s2.0-003611930315758445
  105. C. DonadioM. ArdiniA. LucchesiE. DonadioT. CantorParathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?Clinical Nephrology200767313113910.5414/CNP671312-s2.0-3394720969517390737
  106. S. M. OttBisphosphonate safety and efficacy in chronic kidney diseaseKidney International201282883383510.1038/ki.2012.2532-s2.0-8486698796323018824
  107. R. C. Güerri-FernándezX. NoguésJ. M. Quesada GómezMicroindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controlsJournal of Bone and Mineral Research201328116216810.1002/jbmr.17312-s2.0-8487286569222887720
  108. S. Gourion-ArsiquaudM. R. AllenD. B. BurrD. VashishthS. Y. TangA. L. BoskeyBisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneityBone201046366667210.1016/j.bone.2009.11.0112-s2.0-7764918751719925895
  109. E. ShaneD. BurrB. AbrahamsenAtypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral researchJournal of Bone and Mineral Research201429112310.1002/jbmr.19982-s2.0-8489103417823712442
  110. Z. MahjoubS. JeanJ.-T. LeclercIncidence and characteristics of atypical femoral fractures: clinical and geometrical dataJournal of Bone and Mineral Research201631476777610.1002/jbmr.27482-s2.0-8496382093526588590
  111. H. SatoN. KondoY. WadaThe cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonatesOsteoporosis International20162731217122510.1007/s00198-015-3382-92-s2.0-8495925212726519417
  112. P. AnagnostisJ. C. StevensonBisphosphonate drug holidays-when, why and for how long?Climacteric201518supplement 2323810.3109/13697137.2015.10990922-s2.0-8494858220126507608
  113. S. A. JamalÖ. LjunggrenC. Stehman-BreenEffects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research20112681829183510.1002/jbmr.4032-s2.0-7996002824221491487
  114. R. HiramatsuY. UbaraN. SawaDenosumab for low bone mass in hemodialysis patients: a noncontrolled trialAmerican Journal of Kidney Diseases201566117517710.1053/j.ajkd.2015.03.0122-s2.0-8493751629925979349
  115. G. A. BlockH. G. BoneL. FangE. LeeD. PadhiA single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research20122771471147910.1002/jbmr.16132-s2.0-8486249459022461041
  116. A. IshaniT. BlackwellS. A. JamalS. R. CummingsK. E. EnsrudThe effect of raloxifene treatment in postmenopausal women with CKDJournal of the American Society of Nephrology20081971430143818400939
  117. M. L. MelamedT. BlackwellJ. NeugartenRaloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysisKidney International201179224124910.1038/ki.2010.3782-s2.0-7865087184320927038
  118. K. SumidaY. UbaraJ. HoshinoOnce-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective studyOsteoporosis International20162741441145010.1007/s00198-015-3377-62-s2.0-8496106330426525045
  119. E. MitsopoulosE. GinikopoulouD. EconomidouImpact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot studyAmerican Journal of Nephrology201236323824410.1159/0003418642-s2.0-8486559089122948280
  120. D. CejkaK. KodrasT. BaderM. HaasTreatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot studyKidney and Blood Pressure Research201033322122610.1159/0003167082-s2.0-7795394564720588059
  121. M. R. McClungA. GrauerS. BoonenRomosozumab in postmenopausal women with low bone mineral densityThe New England Journal of Medicine2014370541242010.1056/nejmoa13052242-s2.0-8489304452824382002
  122. C. P. RecknorR. R. ReckerC. T. BensonThe effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral densityJournal of Bone and Mineral Research20153091717172510.1002/jbmr.24892-s2.0-8493064296125707611
  123. C. GraeffG. M. CampbellJ. PeñaAdministration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysisBone20158136436910.1016/j.bone.2015.07.0362-s2.0-8493947724026232375
  124. D. CejkaR. MarculescuN. KozakowskiRenal elimination of sclerostin increases with declining kidney functionThe Journal of Clinical Endocrinology & Metabolism201499124825510.1210/jc.2013-27862-s2.0-8489218151624187403
  125. L. DesjardinsS. LiabeufR. B. OliveiraUremic toxicity and sclerostin in chronic kidney disease patientsNephrologie et Therapeutique201410646347010.1016/j.nephro.2014.04.0022-s2.0-8492280332825070604
  126. R. KoosV. BrandenburgA. H. MahnkenSclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo studyThe Journal of Heart Valve Disease20132233173252-s2.0-8488785021624151757
  127. M. KanbayD. SiriopolM. SaglamSerum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patientsThe Journal of Clinical Endocrinology & Metabolism20149910E1854E186110.1210/jc.2014-20422-s2.0-8490764715525057883
  128. C. DrechslerP. EvenepoelM. G. VervloetHigh levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD studyNephrology Dialysis Transplantation201530228829310.1093/ndt/gfu3012-s2.0-84922549146
  129. S. M. MoeS. AbdallaG. M. ChertowEffects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trialJournal of the American Society of Nephrology20152661466147510.1681/asn.20140404142-s2.0-8493044226125505257
  130. G. J. BehetsG. SpasovskiL. R. SterlingBone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidismKidney International201587484685610.1038/ki.2014.3492-s2.0-8492652876925337774
  131. S. YamamotoR. KidoY. OnishiUse of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patientsPLoS ONE2015104e012269110.1371/journal.pone.01226912-s2.0-84928788342
  132. C. S. RajapakseM. B. LeonardY. A. BhagatW. SunJ. F. MaglandF. W. WehrliMicro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantationRadiology2012262391292010.1148/radiol.111110442-s2.0-8485871227822357891
  133. B. BieleszJ. M. PatschL. FischerCortical porosity not superior to conventional densitometry in identifying hemodialysis patients with fragility fracturePLoS ONE2017122e017187310.1371/journal.pone.0171873
  134. T. JenkinsL. V. CouttsS. D'AngeloSite-dependent reference point microindentation complements clinical measures for improved fracture risk assessment at the human femoral neckJournal of Bone and Mineral Research201631119620310.1002/jbmr.26052-s2.0-8495770953726235931
  135. M. KettelerG. J. ElderP. EvenepoelRevisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: improving Global Outcomes controversies conferenceKidney International201587350250810.1038/ki.2014.4252-s2.0-8493841663825651364
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5380833/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as osteoporosis.